ABSTRACT
Traumatic stress exposures (TSE) are common in life. While most individuals recover following a TSE, a substantial subset develop adverse posttraumatic neuropsychiatric sequelae such as chronic posttraumatic musculoskeletal pain (CPMP). Vulnerability factors for CPMP are poorly understood, which hinders identification of high-risk individuals for targeted interventions. One known vulnerability factor for many pain types is exposure to early life adversity (ELA), but few studies have assessed whether ELA increases risk for CPMP. This study used data from the AURORA study, a prospective human cohort study of TSE survivors, to test the hypothesis that ELA increases risk for CPMP. In addition, in secondary analyses, we assessed which subtypes of ELA (including childhood bullying) were most predictive of CPMP and whether a rat ELA model consisting of neonatal limited bedding (NLB), combined with single prolonged stress (SPS) in adulthood, would accurately model human findings. In AURORA study participants (n=2,480), using multinomial logistic regression modeling of four identified latent pain classes, we found that ELA increased vulnerability to the high unremitting pain class (OR=1.047, p<0.001), the moderate pain class (OR=1.031, p<0.001), and the moderate recovery pain class (OR=1.018, p=0.004), with physical abuse, emotional abuse, and bullying being the strongest predictors of high pain class assignment. Similarly, in male and female Sprague Dawley rats, in comparison to SPS alone NLB combined with SPS caused increased baseline sensitivity and prolonged mechanical hypersensitivity (F(11,197)=3.22, p<0.001). Further studies in animals and humans are needed to understand mechanisms by which ELA confers vulnerability to CPMP.
Summary In humans and rats, early life adversity is associated with a greater duration of musculoskeletal pain and mechanical hypersensitivity following traumatic stress exposures during adulthood.
Competing Interest Statement
Dr. McLean has served as a consultant for Walter Reed Army Institute for Research, Arbor Medical Innovations, and BioXcel Therapeutics, Inc. Dr. Neylan has received research support from NIH, VA, Rainwater Charitable Foundation, Heart and Armor Foundation, and consulting income from Otsuka Pharmaceuticals. Dr. Jovanovic receives support from the National Institute of Mental Health, R01 MH129495. Dr. Germine receives funding from the National Institute of Mental Health (R01 MH121617) and is on the board of the Many Brains Project. Her family also has equity in Intelerad Medical Systems, Inc. Dr. Rauch reported serving as secretary of the Society of Biological Psychiatry; serving as a board member of Community Psychiatry and Mindpath Health; serving as a board member of National Association of Behavioral Healthcare; serving as secretary and a board member for the Anxiety and Depression Association of America; serving as a board member of the National Network of Depression Centers; receiving royalties from Oxford University Press, American Psychiatric Publishing Inc, and Springer Publishing; and receiving personal fees from the Society of Biological Psychiatry, Community Psychiatry and Mindpath Health, and National Association of Behavioral Healthcare outside the submitted work. Dr. Pascual is president elect of the Society for Clinical Care Medicine. In the past 3 years, Dr. Kessler was a consultant for Cambridge Health Alliance, Canandaigua VA Medical Center, Holmusk, Partners Healthcare, Inc., RallyPoint Networks, Inc., and Sage Therapeutics. He has stock options in Cerebral Inc., Mirah, PYM, and Roga Sciences. Dr. Koenen has been a paid scientific consultant for the US Department of Justice and Covington Burling, LLP over the last three years. She receives royalties from Guilford Press and Oxford University Press. Dr. Ressler has performed scientific consultation for Bioxcel, Bionomics, Acer, and Jazz Pharma; serves on Scientific Advisory Boards for Sage, Boehringer Ingelheim, Senseye, and the Brain Research Foundation, and he has received sponsored research support from Alto Neuroscience.
Funding Statement
This work was funded by the National Institute of Mental Health (NIMH; U01MH110925-PIs McLean, Kessler, Ressler, and Koenen), by the National Institute of Neurological Disorders and Stroke (NINDS; R01NS118563-PIs Linnstaedt and McLean), by The Rita Allen Foundation (PI Linnstaedt), by the National Institute of General Medical Sciences (NIGMS; T32GM008450-Fellow McKibben), as well as the US Army MRMC, One Mind, and The Mayday Fund.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The IRB of each of the participating institutions, listed below gave ethical approval for this work: Washington University in St. Louis, Rhode Island Hospital, Miriam Hospital, University of Massachusetts Amherst, Henry Ford Health, Indiana University Hospital, Eskenazi Hospital, Vanderbilt University, University of Florida, Cooper University, Temple University, Jefferson Einstein Philadelphia Hospital, University of Alabama at Birmingham, University of Cincinnati, Corewell Health William Beaumont University Hospital, University of Pennsylvania, Boston Medical Center, Emory University, Thomas Jefferson University Hospital, Ascension St. John Medical Center, St Joseph's Hospital and Medical Center, Massachusetts General Hospital, Brigham and Women's Hospital: Boston Hospital & Medical Center, Detroit Medical Center Sinai-Grace Hospital, The University of Texas Health Science Center at Houston, Beth Israel Deaconess Medical Center, Baystate Health, Detroit Medical Center Detroit Receiving Hospital, Baylor University, Corewell Health Beaumont Troy Hospital, The University of Texas Southwestern Medical Center
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced are available online at https://nda.nih.gov/edit_collection.html?id=2526.
